ADVA
1.4.2020 09:02:08 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that the European Advanced Networking Test Center (EANTC) has validated the interoperability of its unique carrier-grade network operating system (NOS) with routers and network management systems from a wide range of vendors. ADVA’s Ensemble Activator successfully demonstrated interoperability in a series of tests showing how disaggregated packet devices can significantly enhance the scale and functionality of networks. The software-based NOS, which turns bare-metal switches into powerful packet network devices, proved fully compatible with third-party switching and routing devices while supporting segment routing and MPLS Layer 3 services. What’s more, it showed ease of integration into third-party management systems through open interfaces for telemetry streaming and SDN control. Conducted at the EANTC’s facility in Berlin, the tests highlight the value of openness and show how Ensemble Activator can complement legacy packet networks with disaggregated packet devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200401005039/en/
“Putting our Ensemble Activator through EANTC’s rigorous tests emphasizes the commitment to openness and interoperability that underpins all ADVA innovation. But we’re also showing the industry how we can bring something special to Layer 3. Our years of experience with lower layer solutions give us a unique understanding of the operational aspects of networks,” said Eli Angel, VP, product line management, ADVA. “Our Ensemble Activator is proven to enable high-value disaggregated cell site gateway solutions, bringing the agility of software-based feature development to mobile networks. Now, we’re going even further and extending our unique MEF 3.0-certified solution with higher layer networking capabilities. These tests highlight how our Ensemble Activator supports segment routing and MPLS. What more, our disaggregated packet solution releases communication service providers from vendor lock-in and delivers total agility.”
Engineered specifically for white box switching, ADVA’s Ensemble Activator is the result of years of experience in deploying optical, Carrier Ethernet and IP/MPLS networks. The NOS is designed for zero-touch provisioning using the Open Networking Install Environment (ONIE) framework. Its success in the latest round of EANTC tests demonstrates how Ensemble Activator’s open management and control interfaces support easy integration into multi-vendor networks. ADVA’s strategy of extending its software capabilities from Layer 2 to higher layer functions offers the market a fresh approach to deploying flexible, feature-rich software-based MPLS routing and segment routing solutions in an open environment. ADVA’s long experience of building disaggregated telecommunication infrastructure will bring a host of benefits to operators and users of virtual private networks.
“Our evaluation confirms that Ensemble Activator successfully interworked with third-party routers and network management systems. In environments featuring technology from other major vendors, ADVA’s disaggregated software NOS was verified in tests focused on Layer 2 and Layer 3 VPNs, segment routing, and control and data plane capabilities,” commented Carsten Rossenhövel, managing director, EANTC. “This latest interoperability event was a major success with more than 100 attendees from 16 vendors, including many participating remotely. Its program reflected a shift across the industry to software-defined networking with many testing scenarios involving programmability and manageability. ADVA’s Ensemble Activator easily integrated and successfully interoperated in several of these tests, such as those focused on vendor-neutral Layer 3 segment routing and telemetry streaming.”
Further information on the interoperability testing is available on the EANTC website: https://adva.li/eantc-2020 .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About EANTC
EANTC (European Advanced Networking Test Center) is internationally recognized as one of the world's leading independent test centers for telecommunication technologies. Based in Berlin, Germany, the company offers vendor-neutral consultancy and realistic, reproducible high-quality testing services since 1991. Customers include leading network equipment manufacturers, tier-1 service providers, large enterprises and governments worldwide. EANTC's proof of concept, acceptance tests and network audits cover established and next-generation fixed and mobile network technologies. www.eantc.de
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200401005039/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom